Exact Mass: 588.2254
Exact Mass Matches: 588.2254
Found 403 metabolites which its exact mass value is equals to given mass value 588.2254
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Etoposide
Etoposide is a beta-D-glucoside, a furonaphthodioxole and an organic heterotetracyclic compound. It has a role as an antineoplastic agent and a DNA synthesis inhibitor. It is functionally related to a podophyllotoxin and a 4-demethylepipodophyllotoxin. A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Etoposide is a Topoisomerase Inhibitor. The mechanism of action of etoposide is as a Topoisomerase Inhibitor. Etoposide is a natural product found in Aspergillus porosus, Aspergillus alliaceus, and other organisms with data available. Etoposide is a semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum. Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04) A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. See also: Etoposide Phosphate (active moiety of). Etoposide, also known as vepesid or VP-16, belongs to the class of organic compounds known as podophyllotoxins. These are tetralin lignans in which the benzene moiety of the tetralin skeleton is fused to a 1,3-dioxolane and the cyclohexane is fused to a butyrolactone (pyrrolidin-2-one). Etoposide is a drug. Within humans, etoposide participates in a number of enzymatic reactions. In particular, etoposide can be converted into etoposide ortho-quinone; which is mediated by the enzymes prostaglandin g/h synthase 1 and prostaglandin g/h synthase 2. In addition, etoposide and uridine diphosphate glucuronic acid can be converted into etoposide glucuronide and uridine 5-diphosphate; which is mediated by the enzyme UDP-glucuronosyltransferase 1-1. In humans, etoposide is involved in etoposide metabolism pathway. Etoposide is formally rated as a carcinogen (by IARC 1) and is also a potentially toxic compound. Etoposide is used as a form of chemotherapy for cancers such as Kaposis sarcoma, Ewings sarcoma, lung cancer, testicular cancer, lymphoma, nonlymphocytic leukemia, and glioblastoma multiforme. It is given intravenously (IV) or orally in capsule or tablet form. It is believed to work by damaging DNA. Etoposide was approved for medical use in the United States in 1983. They can include low blood cell counts, vomiting, loss of appetite, diarrhea, hair loss, and fever. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01C - Plant alkaloids and other natural products > L01CB - Podophyllotoxin derivatives C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product > C1331 - Epipodophyllotoxin Compound C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C1907 - Drug, Natural Product D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS [Raw Data] CB195_Etoposide_pos_20eV_CB000069.txt [Raw Data] CB195_Etoposide_pos_50eV_CB000069.txt [Raw Data] CB195_Etoposide_pos_10eV_CB000069.txt [Raw Data] CB195_Etoposide_pos_40eV_CB000069.txt [Raw Data] CB195_Etoposide_pos_30eV_CB000069.txt Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1]. Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1].
8,12-Diethylbacteriochlorophyllide d
Sandoricin
Sandoricin is found in fruits. Sandoricin is a constituent of Sandoricum koetjape (santol). Constituent of Sandoricum koetjape (santol). Sandoricin is found in fruits.
Antrafenine
Antrafenine is only found in individuals that have used or taken this drug. It is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen. It is not widely used as it has largely been replaced by newer drugs.Antrafenine is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals. The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity. C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
Chlorophyll c
Chlorophyll c is widely distributed photosynthetic pigment in marine organisms, e.g. the diatom Nitzschia closteriu
Pentigetide
D007155 - Immunologic Factors > D007132 - Immunoglobulin Isotypes C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D007155 - Immunologic Factors > D007136 - Immunoglobulins D007155 - Immunologic Factors > D000906 - Antibodies Immunoglobulin E fragment. Immunoglobulin E fragment Pentigetide is a sythsis pepetide (Asp-Ser-Asp-Pro-Arg or D-S-D-P-R), also know as “HEPP” for “Human IgE Pentapeptide”. Pentigetide can not produce IgE inhibition in several different systems, due to the aspartic acids in HEPP changed into an asparagine[1].
(1RS,2RS)-2-(4-Hydroxyphenyl)-2-methyl-1-(9-(4,4,5,5,5-pentafluoropentyl)sulfinylnonyl)-1,2,3,4-tetrahydronaphth-6-ol
Cfp-aaf-pab
N(2)-(4-Hydroxy-1-(1-methyl-1H-indol-3-yl)carbonyl-L-prolyl)-N-methyl-N-phenylmethyl-3-(2-naphthyl)-L-alaninamide
Ziritaxestat
C78273 - Agent Affecting Respiratory System
1,1'-(Propane-1,3-diylbis(oxy))bis(7-methoxy-2-methylene-1,2,3,11a-tetrahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H)-dione)
Matteuorienate C
Blestrianol B
1alpha-acetoxy-6beta,9beta-difuroyloxy-2alpha-propyonyloxy-4beta-hydroxy-dihydro-beta-agarofuran
14-O-methylacetal-15-O-[6-(p-hydroxyphenylacetyl)]-beta-D-glucopyranosylurospermal A
bis-5,6-dihydro-2(1H)-pyridonyl-trans-trans-trans-2-(3-methoxy-4,5-methylenedioxyphenyl)-4-(3,4-dimethoxyphenyl)-1,3-cyclobutanedicarboxamide|piperarborenine E
5,7,10-Triacetoxy-5a-(acetoxymethyl)-6-(benzoyloxy)-3,4,5,5a,6,7,8,9-octahydro-2,2,9-trimethyl-2H-3,9a-methano-1-benzooxepin-4-one
9-Deacetyl-9-benzoyl-10-debenzoyl-4beta,20-epoxytaxchinin A
(1R,2S,4R,5S,6R,7R,9S,10S)-9-benzoyloxy-1,2,6,15-tetraacetoxy-8-oxo-dihydro-beta-agarofuran
2-O-E-caffeoyl-8alpha-hydroxy-11alpha,13-dihydro-3beta-O-beta-D-glucozaluzanin C
beta-Gal-(1-3)-(beta-GlcNAc-(1-6))-GalNAc-ol|beta-Gal-(1-3)--GalNAc-ol
6-Methoxy-3,4-(methylene(6-methoxyisoquinoline-1,7-diyl)oxy(2-methyl-6,7-(epoxymethanoxy)-1,2,3,4-tetrahydroisoquinoline-8,1-diyl)methylene)(1,1-oxybisbenzene)
pre-schisanartanin|pre-schisanartanin A|preschisanartanin A
5alpha-acetyl-1beta,8alpha-bis-cinnamoyl-4alpha-hydroxydihydroagarofuran|5??-Acetyl-1??,8??-bis-cinnamoyl-4??-hydroxydihydroagarofuran
(-)-3-O-beta-D-glucopyranosyl 8-[(2S),3-dihydroxy-3-methylbutyl]-7-hydroxychromen-2-one 7-O-beta-D-glucopyranoside|devenyoside C
3-O-beta-glucopyranosyl-8-O-beta-(4-hydroxyphenyl)-lactyl-1alphaH,5alphaH,6betaH,7alphaH-guai-3(4),10(14),11(13)-triene-15-methyl-6,12-olide|lapsanoside B
N, N, N-p-hydroxybenxoyl,caffeoyl, feruloylagmatine
Etoposide
Annotation level-1 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.968 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.967 Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1]. Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1].
C31H40O11_7,11-Methano-2H,4H-oxireno[1,8]cycloocta[1,2-f][2]benzopyran-8-acetic acid, 4-(3-furanyl)dodecahydro-alpha,11-dihydroxy-4a,7,9,9-tetramethyl-10-(2-methyl-1-oxopropoxy)-2,13-dioxo-, methyl ester, (alphaR,4R,4aR,7S,8S,10S,11S,11aR,12aS)
(1S,2R,4S,9R,10R,14S,15S,17S)-9-(furan-3-yl)-1-hydroxy-15-[(1R)-1-hydroxy-2-methoxy-2-oxoethyl]-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl 2-methylpropanoate
Antrafenine
C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
(1S,2R,4S,9R,10R,14S,15S,17S)-9-(furan-3-yl)-1-hydroxy-15-[(1R)-1-hydroxy-2-methoxy-2-oxoethyl]-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl 2-methylpropanoate_major
(1S,2R,4S,9R,10R,14S,15S,17S)-9-(furan-3-yl)-1-hydroxy-15-[(1R)-1-hydroxy-2-methoxy-2-oxoethyl]-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,?.0?,¹³.0?,¹?]octadecan-17-yl 2-methylpropanoate
Asp Glu Tyr Tyr
Asp Tyr Glu Tyr
Asp Tyr Tyr Glu
Glu Asp Tyr Tyr
Glu Phe Phe Phe
Glu Phe Met Tyr
Glu Phe Tyr Met
Glu Met Phe Tyr
Glu Met Tyr Phe
Glu Tyr Asp Tyr
Glu Tyr Phe Met
Glu Tyr Met Phe
Glu Tyr Tyr Asp
Phe Glu Phe Phe
Phe Glu Met Tyr
Phe Glu Tyr Met
Phe Phe Glu Phe
Phe Phe Phe Glu
Phe Met Glu Tyr
Phe Met Tyr Glu
Phe Pro Tyr Tyr
Phe Tyr Glu Met
Phe Tyr Met Glu
Phe Tyr Pro Tyr
Phe Tyr Tyr Pro
Ile Met Tyr Tyr
Ile Tyr Met Tyr
Ile Tyr Tyr Met
Leu Met Tyr Tyr
Leu Tyr Met Tyr
Leu Tyr Tyr Met
Met Glu Phe Tyr
Met Glu Tyr Phe
Met Phe Glu Tyr
Met Phe Tyr Glu
Met Ile Tyr Tyr
Met Leu Tyr Tyr
Met Tyr Glu Phe
Met Tyr Phe Glu
Met Tyr Ile Tyr
Met Tyr Leu Tyr
Met Tyr Tyr Ile
Met Tyr Tyr Leu
Pro Phe Tyr Tyr
Pro Thr Trp Trp
Pro Trp Thr Trp
Pro Trp Trp Thr
Pro Tyr Phe Tyr
Pro Tyr Tyr Phe
Gln Gln Gln Trp
Gln Gln Trp Gln
Gln Trp Gln Gln
Thr Pro Trp Trp
Thr Trp Pro Trp
Thr Trp Trp Pro
Trp Pro Thr Trp
Trp Pro Trp Thr
Trp Gln Gln Gln
Trp Thr Pro Trp
Trp Thr Trp Pro
Trp Trp Pro Thr
Trp Trp Thr Pro
Tyr Asp Glu Tyr
Tyr Asp Tyr Glu
Tyr Glu Asp Tyr
Tyr Glu Phe Met
Tyr Glu Met Phe
Tyr Glu Tyr Asp
Tyr Phe Glu Met
Tyr Phe Met Glu
Tyr Phe Pro Tyr
Tyr Phe Tyr Pro
Tyr Ile Met Tyr
Tyr Ile Tyr Met
Tyr Leu Met Tyr
Tyr Leu Tyr Met
Tyr Met Glu Phe
Tyr Met Phe Glu
Tyr Met Ile Tyr
Tyr Met Leu Tyr
Tyr Met Tyr Ile
Tyr Met Tyr Leu
Tyr Pro Phe Tyr
Tyr Pro Tyr Phe
Tyr Tyr Asp Glu
Tyr Tyr Glu Asp
Tyr Tyr Phe Pro
Tyr Tyr Ile Met
Tyr Tyr Leu Met
Tyr Tyr Met Ile
Tyr Tyr Met Leu
Tyr Tyr Pro Phe
Sandoricin
Pentyde
D007155 - Immunologic Factors > D007132 - Immunoglobulin Isotypes C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D007155 - Immunologic Factors > D007136 - Immunoglobulins D007155 - Immunologic Factors > D000906 - Antibodies Pentigetide is a sythsis pepetide (Asp-Ser-Asp-Pro-Arg or D-S-D-P-R), also know as “HEPP” for “Human IgE Pentapeptide”. Pentigetide can not produce IgE inhibition in several different systems, due to the aspartic acids in HEPP changed into an asparagine[1].
(2aR,3R,6bS,7aR,8S,9S,11S,12S)-3-(furan-3-yl)-8-hydroxy-11-((R)-1-hydroxy-2-methoxy-2-oxoethyl)-2a,10,10,12-tetramethyl-5,13-dioxododecahydro-2H,3H-8,12-methanooxireno[2,3:1,8]cycloocta[1,2-f]isochromen-9-yl isobutyrate
(r)-(+)-7,7-bis(diphenylphosphino)-2,2,3,3-tetrahydro-1,1-spirobiindane
Procaine penicillin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
[3-methyl-4-[4-(3-prop-2-enoyloxypropoxy)benzoyl]oxyphenyl] 4-(3-prop-2-enoyloxypropoxy)benzoate
N,N-Bis(naphthalene-2-yl)-N,N-bis(phenyl)benzidine
1,1-(1,3-Propanediyl)bis[1,1-bis(2-methoxy-5-methylphenyl)phosphine]
Chloro[(tricyclohexylphosphine)-2-(2-aminobiphenyl)]palladium(II)
(7-diphenylphosphanyl-1,3-spirobi[indane]-4-yl)-diphenyl-phosph ane
Etoposide Impurity B
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D004791 - Enzyme Inhibitors
(2S,4R)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-4-hydroxy-1-(1-methylindole-3-carbonyl)pyrrolidine-2-carboxamide
2-[(8S,11S)-11-{(1R)-1-Hydroxy-2-[isopentyl(phenylsulfonyl)amino]ethyl}-6,9-dioxo-2-oxa-7,10-diazabicyclo[11.2.2]heptadeca-1(15),13,16-trien-8-YL]acetamide
N-[4-({[(6s)-2-Amino-5-Methyl-4-Oxo-1,4,5,6,7,8-Hexahydropteridin-6-Yl]methyl}amino)benzoyl]-L-Gamma-Glutamyl-L-Glutamic Acid
(2S)-2-[[(2S)-2-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid
3-[11,16-Bis(ethenyl)-4-hydroxy-3-methoxycarbonyl-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18,20(23),21-dodecaen-22-yl]propanoic acid
(1RS,2RS)-2-(4-Hydroxyphenyl)-2-methyl-1-(9-(4,4,5,5,5-pentafluoropentyl)sulfinylnonyl)-1,2,3,4-tetrahydronaphth-6-ol
(5S,5aR,8aR,9R)-5-[(7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[6,5-f][1,3]benzodioxol-8-one
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D004791 - Enzyme Inhibitors
(8aR,9R)-9-[4-hydroxy-3,5-bis(methyloxy)phenyl]-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3,4:6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside
trigoheterin E, (rel)-
A natural product found in Trigonostemon heterophyllus.
Methyl 2-[(1S,3S,5S,7S,8S,9R,11S,12S,13R,16S)-5,11-diacetyloxy-13-(furan-3-yl)-16-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.01,12.03,8]heptadecan-7-yl]acetate
2-(4-methoxyphenyl)-N-[2-(4-morpholinyl)-5-(4-morpholinylsulfonyl)phenyl]-4-quinolinecarboxamide
2-[(2R,4aR,12aR)-8-[(3-fluorophenyl)sulfonylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
(2S)-2-[(4R,5S)-4-methyl-5-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(8aR,9R)-5-[(7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrobenzofuro[6,5-f][1,3]benzodioxol-8-one
2-[(2S,4aR,12aS)-8-[(3-fluorophenyl)sulfonylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(2-piperidin-1-ylethyl)acetamide
(2S)-2-[(4S,5R)-4-methyl-5-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
N-[(2S,3R)-2-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2R,3R)-2-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(5S,6R,9R)-8-(4-fluorophenyl)sulfonyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
2-[(2S,4aR,12aR)-8-[(3-fluorophenyl)sulfonylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(2R,4aS,12aS)-8-[(3-fluorophenyl)sulfonylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
N-[(2R,3S)-2-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-1,3-benzothiazole-2-carboxamide
N-[(2R,3R)-2-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3S)-2-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2S,3R)-2-[[[(1,3-benzodioxol-5-ylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-2-phenylacetamide
N-[(2R,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide
N-[(5S,6R,9R)-8-(3-fluorophenyl)sulfonyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-3-isoxazolecarboxamide
2-[(2S,4aS,12aR)-8-[(3-fluorophenyl)sulfonylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(2R,4aR,12aS)-8-[(3-fluorophenyl)sulfonylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(2R,4aS,12aR)-8-[(3-fluorophenyl)sulfonylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
2-[(2S,4aS,12aS)-8-[(3-fluorophenyl)sulfonylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-[2-(1-piperidinyl)ethyl]acetamide
N-[9-(3-{[2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl]amino}-3-oxopropyl)-6-(ethylamino)-2,7-dimethyl-3H-xanthen-3-ylidene]ethanaminium perchlorate
(5S,5aS,8aS,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
N-[(2R,3R,4R,5R,6R)-2-[(2R,3R,4R,5R,6R)-6-[(2S,3R,4S,5R)-2-Acetamido-1,4,5,6-tetrahydroxyhexan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-D-GalNAc-OH
N-[(2S,3R,4R,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[(2S,3R,4S,5R)-2-Acetamido-1,4,5,6-tetrahydroxyhexan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
N-[(2R,3R,4R,5S,6R)-2-[(2R,3R,4R,5S)-5-Acetamido-2,3,4,6-tetrahydroxyhexoxy]-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide
N-[(2R,3R,4R,5S,6R)-2-[(2R,3R,4R,5R,6R)-6-[(2S,3R,4S,5R)-2-Acetamido-1,4,5,6-tetrahydroxyhexan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
N-[(3R,4R,5S,6R)-2-[(2R,3S,4R,5S)-5-Acetamido-2,3,6-trihydroxy-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
N-[(2R,3R,4R,5R,6R)-2-[(2R,3S,4R,5S)-5-Acetamido-2,3,6-trihydroxy-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
N-[(2R,3R,4R,5S,6R)-2-[(2R,3R,4R,5S)-5-Acetamido-2,4,6-trihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcNAc-OH
N-[(3R,4R,5S,6R)-2-[(2S,3R,4S,5R)-2-Acetamido-1,4,5,6-tetrahydroxyhexan-3-yl]oxy-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide
(E)-3-(16-ethenyl-11-ethyl-4-hydroxy-3-methoxycarbonyl-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18,20(23),21-dodecaen-22-yl)prop-2-enoic acid
[5R-[5alpha,5abeta,8aalpha,9beta(R*)]]-9-[(4,6-O-Ethylidene-beta-d-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo[3,4:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
[(1S,2R,4S,5R,9R,10R,14S,15S,17S)-9-(furan-3-yl)-1-hydroxy-15-[(1R)-1-hydroxy-2-methoxy-2-oxoethyl]-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.02,4.04,13.05,10]octadecan-17-yl] 2-methylpropanoate
2-[hydroxy-[3-hydroxy-2-[(Z)-16-(81Br)bromanyl-5-hydroxyhexadec-12-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[(Z)-16-(79Br)bromanyl-5-hydroxyhexadec-12-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
Pentigetide
D007155 - Immunologic Factors > D007132 - Immunoglobulin Isotypes C308 - Immunotherapeutic Agent > C574 - Immunosuppressant D007155 - Immunologic Factors > D007136 - Immunoglobulins D007155 - Immunologic Factors > D000906 - Antibodies Pentigetide is a sythsis pepetide (Asp-Ser-Asp-Pro-Arg or D-S-D-P-R), also know as “HEPP” for “Human IgE Pentapeptide”. Pentigetide can not produce IgE inhibition in several different systems, due to the aspartic acids in HEPP changed into an asparagine[1].
Bemfivastatin
Bemfivastatin (PPD 10558) is an orally active, HMG-CoA Reductase (HMGCR) inhibitor, also known as Statin. Bemfivastatin enhances the activity of liver extraction. Bemfivastatin exhibits little developmental toxicity effects in pregnant rats and rabbits via daily oral doses during organogenesis period. The no observed adverse effect level (NOAEL) are ≥320?mg/kg/day for rats developmental toxicity, 12.5?mg/kg/day for rabbits maternal toxicity, and 25?mg/kg/day for rabbits developmental toxicity, respectively. Bemfivastatin can be used for research on Statin-related hypercholesterolemic myalgia with inability to tolerate statins[1][2].
(3,4,5-trihydroxy-6-{[(1s,2r,6r,7z,11e)-13-methoxy-3-methylidene-4-oxo-5,14-dioxatricyclo[10.2.1.0²,⁶]pentadeca-7,11-dien-8-yl]methoxy}oxan-2-yl)methyl 2-(4-hydroxyphenyl)acetate
(10e)-17-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}tricyclo[12.3.1.1²,⁶]nonadeca-1(18),2(19),3,5,10,14,16-heptaen-9-one
ethyl (1r,3r,4s,5r)-3-{[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-1,4-dihydroxy-5-{[(2e)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoyl]oxy}cyclohexane-1-carboxylate
4,7,12-tris(acetyloxy)-6-[(acetyloxy)methyl]-2,10,10-trimethyl-8-oxo-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl benzoate
(1r,2s,6s,7s,10r,11s,16s,18r,19r,20r)-18-(acetyloxy)-6-(furan-3-yl)-2,20-dihydroxy-7,17,17-trimethyl-4,14-dioxo-5,13,21-trioxahexacyclo[17.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶.0¹¹,²⁰]docosan-19-yl acetate
(13r,23s)-3,13,19,23-tetrahydroxy-5,7,29-trimethoxy-13,23-dimethyl-16-oxahexacyclo[15.12.0.0²,¹¹.0⁴,⁹.0¹⁸,²⁷.0²⁰,²⁵]nonacosa-1(17),2(11),3,5,7,9,18,20(25),26,28-decaene-15,21-dione
(1r,6r,13r)-13-hydroxy-16,17-dimethoxy-6-(3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}prop-1-en-2-yl)-2,7,20-trioxapentacyclo[11.8.0.0³,¹¹.0⁴,⁸.0¹⁴,¹⁹]henicosa-3(11),4(8),9,14,16,18-hexaen-12-one
3,13,19,23-tetrahydroxy-5,7,29-trimethoxy-13,23-dimethyl-16-oxahexacyclo[15.12.0.0²,¹¹.0⁴,⁹.0¹⁸,²⁷.0²⁰,²⁵]nonacosa-1(17),2(11),3,5,7,9,18,20(25),26,28-decaene-15,21-dione
(1r,2s,3s,5s,8r,9s,10r,11s,13r,16s)-11,16-bis(acetyloxy)-5,8,9-trihydroxy-3-(2-hydroxypropan-2-yl)-6,10-dimethyl-14-oxatetracyclo[8.6.0.0³,⁷.0¹³,¹⁶]hexadec-6-en-2-yl benzoate
8'-[(4-hydroxyphenyl)methyl]-4,5'-dimethoxy-9h,9'h,10h,10'h-[1,3'-biphenanthrene]-2,2',7,7'-tetrol
methyl 2-[(1s,3r,4s,5s,7s,8s,9r,12s,13s,16s)-4,16-bis(acetyloxy)-13-(furan-3-yl)-5-hydroxy-6,6,8,12-tetramethyl-17-methylidene-15-oxo-2,14-dioxatetracyclo[7.7.1.0¹,¹².0³,⁸]heptadecan-7-yl]acetate
1-[(1s,2s,3r,4r)-2-(3,4-dimethoxyphenyl)-4-(7-methoxy-2h-1,3-benzodioxol-5-yl)-3-(2-oxo-5,6-dihydropyridine-1-carbonyl)cyclobutanecarbonyl]-5,6-dihydropyridin-2-one
(1s,2r,4s,5r,9r,10r,13r,14s,15s,17s)-9-(furan-3-yl)-1-hydroxy-15-[(1r)-1-hydroxy-2-methoxy-2-oxoethyl]-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-17-yl 2-methylpropanoate
ethyl (1s,3r,4r,5r)-3-{[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-1,5-dihydroxy-4-{[(2e)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoyl]oxy}cyclohexane-1-carboxylate
(1r,2s,3r,10s,19r,22s,23s,24r,26r,29r)-10-acetyl-1,22-dihydroxy-2,22-dimethyl-5,16-dioxo-4,11,17,25-tetraoxahexacyclo[21.3.1.1³,²⁶.1¹⁰,¹⁴.0²,¹⁹.0¹⁹,²⁴]nonacosa-6,14-dien-29-yl acetate
7-[(acetyloxy)methyl]-4-({[3,4-bis(acetyloxy)-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-7-hydroxy-1h,4ah,5h,6h,7ah-cyclopenta[c]pyran-1-yl 3-methylbutanoate
(3ar,4r,6ar,9ar,9br)-9-methyl-3,6-dimethylidene-2-oxo-8-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3ah,4h,5h,6ah,7h,9ah,9bh-azuleno[4,5-b]furan-4-yl (2r)-2-hydroxy-3-(4-hydroxyphenyl)propanoate
(1r,2s,4r,5s,6r,7r,9s,12s)-4,7,12-tris(acetyloxy)-6-[(acetyloxy)methyl]-2,10,10-trimethyl-8-oxo-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-5-yl benzoate
(1r,4as,7r,7as)-7-[(acetyloxy)methyl]-4-({[(2r,3r,4r,5r,6r)-3,4-bis(acetyloxy)-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-7-hydroxy-1h,4ah,5h,6h,7ah-cyclopenta[c]pyran-1-yl 3-methylbutanoate
(1s,3r,5s,6s,7s,9r,10r,13r,14r,16s,18r,20r,22s,24s,26s)-7,13,26-trihydroxy-1-methoxy-5,9,24-trimethyl-10-(6-oxopyran-3-yl)-2,15,21,23-tetraoxaheptacyclo[20.3.1.0³,²⁰.0⁵,¹⁸.0⁶,¹⁴.0⁹,¹³.0¹⁴,¹⁶]hexacosan-8-one
methyl 2-[4,5-bis(acetyloxy)-12-(furan-3-yl)-6,6,8,11,16-pentamethyl-14,17-dioxo-2,13-dioxatetracyclo[7.6.2.0¹,¹¹.0³,⁸]heptadecan-7-yl]acetate
5-(acetyloxy)-12-(furan-2-carbonyloxy)-2-hydroxy-2,6,10,10-tetramethyl-4-(propanoyloxy)-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl furan-2-carboxylate
1,6,6',9,9'-pentahydroxy-1',3,3'-trimethoxy-6,6'-dimethyl-5h,5'h,7h,7'h-[2,2'-bianthracene]-8,8'-dione
1-[2-(furan-3-yl)-2-hydroxyethyl]-2,5-dihydroxy-5-(methoxycarbonyl)-1,4a-dimethyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-hexahydronaphthalene-2-carboxylic acid
14-o-methylacetal-15-o-[6'-(p-hydroxyphenyl-acetyl)]-β-d-glucopyranosylurospermal a
{"Ingredient_id": "HBIN001541","Ingredient_name": "14-o-methylacetal-15-o-[6'-(p-hydroxyphenyl-acetyl)]-\u03b2-d-glucopyranosylurospermal a","Alias": "NA","Ingredient_formula": "C30H36O12","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "14103","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5α-acetyl-1β,8α-bis-cinnamoyl-4α-hydroxydi-hydroagarofuran
{"Ingredient_id": "HBIN011403","Ingredient_name": "5\u03b1-acetyl-1\u03b2,8\u03b1-bis-cinnamoyl-4\u03b1-hydroxydi-hydroagarofuran","Alias": "NA","Ingredient_formula": "C35H40O8","Ingredient_Smile": "CC(=O)OC1C2CC(C3(C1(C(CCC3OC(=O)C=CC4=CC=CC=C4)(C)O)OC2(C)C)C)OC(=O)C=CC5=CC=CC=C5","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "334","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
7,9,10-deacetylbaccatin vi
{"Ingredient_id": "HBIN012995","Ingredient_name": "7,9,10-deacetylbaccatin vi","Alias": "NA","Ingredient_formula": "C31H40O11","Ingredient_Smile": "CC1=C2C(C(C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C)O)OC(=O)C5=CC=CC=C5)(CO4)OC(=O)C)O)C)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4724","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
7,9,13-trideacetylbaccatin vi
{"Ingredient_id": "HBIN012999","Ingredient_name": "7,9,13-trideacetylbaccatin vi","Alias": "NA","Ingredient_formula": "C31H40O11","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21587","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
7,9-diacetyltaxayuntin
{"Ingredient_id": "HBIN013003","Ingredient_name": "7,9-diacetyltaxayuntin","Alias": "NA","Ingredient_formula": "C31H40O11","Ingredient_Smile": "CC1=C2C(C(C3(C(CC4C(C3C(C2(CC1O)C(C)(C)O)OC(=O)C)(CO4)OC(=O)C)O)C)O)OC(=O)C5=CC=CC=C5","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15014","TCMID_id": "5347","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
7-epi-9,10-deacetylbaccatin vi
{"Ingredient_id": "HBIN013170","Ingredient_name": "7-epi-9,10-deacetylbaccatin vi","Alias": "NA","Ingredient_formula": "C31H40O11","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "6880","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
amritoside b
{"Ingredient_id": "HBIN015910","Ingredient_name": "amritoside b","Alias": "NA","Ingredient_formula": "C27H40O14","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1085","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
arteminolide b
{"Ingredient_id": "HBIN016946","Ingredient_name": "arteminolide b","Alias": "NA","Ingredient_formula": "C35H40O8","Ingredient_Smile": "CC1=C2C(C3C(C(C1)OC(=O)C=C(C)C)C4(CC56C=CC4(C5C7C(CCC6(C)O)C(=C)C(=O)O7)C)C(=O)O3)C(=CC2=O)C","Ingredient_weight": "588.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1790","TCMSP_id": "NA","TCM_ID_id": "10104;10105;10106;10107;16347;16348","PubChem_id": "24941963","DrugBank_id": "NA"}
arteminolide d
{"Ingredient_id": "HBIN016948","Ingredient_name": "arteminolide d","Alias": "NA","Ingredient_formula": "C35H40O8","Ingredient_Smile": "CC=C(C)C(=O)OC1CC(=C2C(C3C1C4(CC56C=CC4(C5C7C(CCC6(C)O)C(=C)C(=O)O7)C)C(=O)O3)C(=CC2=O)C)C","Ingredient_weight": "588.7 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1791","TCMSP_id": "NA","TCM_ID_id": "10110;10111;10112;10113;16349;16350","PubChem_id": "24941966","DrugBank_id": "NA"}